[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1990

Changes in Cutaneous Kaposi's Sarcoma in a Patient Infected With the Human Immunodeficiency Virus: Follow-up to a Controlled Hyperimmunization Trial

Author Affiliations

Infectious Disease Division Los Angeles County Olive View Medical Center Sylmar, CA 91342

Biomedical Sciences Division Algorithms Inc Northridge, CA 91325

Arch Dermatol. 1990;126(6):833-834. doi:10.1001/archderm.1990.01670300133032
Abstract

To the Editor.—  Kaposi's sarcoma (KS) is a neoplasm characterized by a proliferation of fibroblastic and microvascular elements with abnormal endothelial cells, extravasated erythrocytes, and spindle-shaped cell infiltration. Kaposi's sarcoma may be systemic with many foci in the mucous membranes, lymph nodes, or visceral organs. In current epidemiology, however, a virulent cutaneous form found on the extremities, trunk, neck, head, or in the oral cavity is a sign of acquired immunodeficiency syndrome (AIDS) in patients infected with the human immunodeficiency virus (HIV).1,2Treatment for KS-AIDS has included chemotherapy, radiation therapy, antiretroviral agents, and immunomodulators in patients with indolent disease.3,4 Because of severely depressed cell-mediated immunity, KS-AIDS patients have a poor tolerance for the myelosuppressive effects of standard antineoplastic agents.5 Recombinant interferon alfa has been the most thoroughly studied of the nonsuppressive immunomodulators, and is most likely to be beneficial in the absence of systemic disease and opportunistic

First Page Preview View Large
First page PDF preview
First page PDF preview
×